Imbalance In The CDMO Market And The Long-Term Implications https://lnkd.in/e7_ixc-j - By Alex Klarer, Founder, Managing Director, Engelex Total cell and gene therapy fundraising up to the second quarter of 2024.
Cell & Gene
Online Audio and Video Media
Erie, Pennsylvania 24,421 followers
The most valuable resource for professionals who make their living in the cell & gene therapies industry.
About us
The landscape of the life sciences industry is as vast and varied as the professionals who work in it. Some online resources aim to serve the entire space. We wish them luck. Instead, our goal is to be the most valuable resource for a specific segment of the industry – cell & gene therapies – and the professionals who make their living there. The Cell & Gene community is not made up of generalists. They’re specialists, like us. We deliver in-depth content from authoritative authors and sources because that’s what our community demands.
- Website
-
https://www.cellandgene.com/
External link for Cell & Gene
- Industry
- Online Audio and Video Media
- Company size
- 51-200 employees
- Headquarters
- Erie, Pennsylvania
Updates
-
In this edition of Cell & Gene "In Focus": TRENDING CONTENT - Catch Up #1. Muscular Dystrophy: Multi-National And Multi-Site Trials #2. What's In The Leukopak Matters For Cell Therapy Manufacturing #3. Cell and Gene Therapies – Global Clinical Trial Landscape (2024) #4. iPSC-based Gene Therapy: Applications And Challenges #5. A "Particular" Problem For Cell Therapy Products, Part 2: Cell Clumps And Other Inherent Particles #6. Comparing In-house Vs. Outsourced Manufacturing Strategies For CGTs
-
Join our webinar, Harnessing mRNA Quality Insights: Essential Techniques for Rapid Drug Development to gain critical insights and skills. 📅 Date: November 11, 2024 🕚 Time: 11:00am ET In this session, you’ll: ✔️ Gain Quality Insights for mRNA and LNPs to improve safety and efficacy. ✔️ Master Key Techniques like Sanger sequencing, mass spectrometry, and qPCR. ✔️ Optimize Development by troubleshooting early and accelerating progress. 🔗 Register Now! https://lnkd.in/dbcR5xW8 Don’t miss out on this opportunity to enhance your approach to mRNA-based therapeutics!
-
-
The FDA's new draft guidance for the Platform Technology Designation Program helps drug developers leverage platform data to speed approvals and improve patient access. In an upcoming webinar, experts will discuss platform processes and supply chain integration and share insights on combining AAV gene therapy with cytokine immunotherapy to treat cancer. #Catalent #cytokine #AAV
This content isn’t available here
Access this content and more in the LinkedIn app
-
Regeneron's Strategy To Address Congenital Deafness https://lnkd.in/e4XRtsXA - By Tyler Menichiello, contributing editor While DB-OTO targets a rare disease, the company views it as a stepping stone toward treating other forms of genetic deafness and, eventually, multifactorial hearing loss, such as age-related or noise-induced, impacting millions globally.
-
-
Adeno-associated virus (AAV) is a prominent vector for gene delivery to treat life-threatening genetic diseases. A limitation for product development and treatment availability is the need for high levels of infectious AAV particles. We’ll show that feeding cell cultures post-transfection (HEK293 cells) or post-infection (insect cells) can boost AAV titers. Data will be shared on the optimization of using Cellvento® ModiFeed Prime COMP to boost AAV titers. #MilliporeSigma #AAV #HEK293 #sf9platforms
This content isn’t available here
Access this content and more in the LinkedIn app
-
Cell & Gene reposted this
This content isn’t available here
Access this content and more in the LinkedIn app
-
Maintaining Harmony With Your CDMO Using 'The Middle Way' https://lnkd.in/eWh_CRrD - By Steven Erb, Ph.D., Crown Point Biotech Consulting LLC The soft skills we use to manage and cultivate our internal and external relationships are often overlooked or undervalued in biotech as we try to meet impossible deadlines with tight resources.
-
-
Cell & Gene reposted this
This article by Engelex's Founder and Managing Director, Alex Klarer explores how the disparity between the number of #CDMOs and #CGT #clinicaltrials came about and how the market for #manufacturing services will change as a result. #cellandgenetherapy #celltherapymanufacturing #AI #valuechain https://lnkd.in/ePX-rwdJ
Imbalance In The CDMO Market And The Long-Term Implications
cellandgene.com